Cambridge Cognition Holdings plc has entered into a commercial agreement with India-based brain health startup Ivory to scale deployment of its digital cognitive assessment platform, CANTAB Pathway™, across healthcare and consumer health markets in India.
The partnership aims to address a significant and growing burden of cognitive impairment in the country. India, with a population of approximately 1.47 billion, has an estimated 138 million people aged over 60. Research from the LASI-DAD study published in PLOS One suggests that as many as 34 million older adults in India may be living with mild or major cognitive impairment. Multiple studies further indicate that up to 90% of cognitive impairment cases remain underdiagnosed, underscoring the need for accessible and scalable early screening solutions.
Under the agreement, Ivory will deploy CANTAB Pathway™ across both professional healthcare settings and consumer health channels. The rollout will leverage Ivory’s expanding clinical network, partnerships with hospitals and diagnostic centers, and its consumer-facing digital platform. The initiative is positioned to meet rising demand for proactive brain health tools among India’s expanding middle and affluent class, estimated at 90–190 million people, as well as increasingly tech-enabled urban populations focused on longevity, healthspan and preventive healthcare.
CANTAB Pathway™ is designed as a scalable cognitive assessment suite structured in escalating modules suitable for both consumer and clinical use. It includes CANTAB One™, a brief assessment of overall cognitive function; CANTAB Insight™, a three-task battery offering deeper analysis across five cognitive sub-domains; and CANTAB Plus™, a set of specialist, disease-specific modules intended for qualified healthcare professionals. The platform supports evaluation across eight indications, including Parkinson’s disease, attention deficit hyperactivity disorder, multiple sclerosis, Huntington’s disease, schizophrenia, depression, and Alzheimer’s disease and related dementias.
The digital assessments are designed to require minimal specialist administration, deliver objective results in real time or shortly after completion, reduce administrator bias, and enable longitudinal monitoring of cognitive function. Outputs can be formatted for both home-based consumer use and clinical or research environments. Relevant to the India launch, assessments are available in English and several Indian languages, including Hindi, Tamil, Telugu, Bengali and Kannada, with further language expansion planned.
Ivory, formally incorporated as Nostalgic Dust Private Limited, was founded in October 2022 and focuses on early detection and proactive cognitive care through neuroscience-based digital assessments and personalized brain training programs delivered via its app. The company reports that its clinical team collectively brings more than 80 years of experience across neuroscience, medicine and neuropsychology. Ivory has received backing from investors including Capital A and TDV Partners and has gained national visibility following its appearance on Shark Tank India (Season 4). It has also received industry recognition, most recently as a winner at the Meet the Drapers Awards.
Cambridge Cognition, headquartered in Cambridge, England, develops touchscreen and voice-based digital cognitive assessments under the CANTAB and Winterlight brands. Its tools are used to support scientific research, drug development and clinical care globally. The India partnership represents a strategic expansion into high-growth international healthcare and consumer markets, aligning with growing demand for earlier identification of cognitive decline and preventive brain health management.
With no definitive cure currently available for many neurodegenerative conditions, including dementia, the focus in many healthcare systems is shifting toward prevention, early identification and long-term monitoring. The collaboration between Cambridge Cognition and Ivory is intended to standardize cognitive assessment at scale in India, improve early detection rates and support more timely clinical intervention in populations at risk.
